How to Fight a Biologic Denial: Humira, Stelara, Dupixent & Other Specialty Drugs

Specialty biologics—drugs like Humira (adalimumab), Enbrel (etanercept), Stelara (ustekinumab), Skyrizi (risankizumab), Cosentyx (secukinumab), Rinvoq (upadacitinib), and Dupixent (dupilumab)—cost between $50,000 and $120,000 per year. Insurers deny them at extraordinarily high rates, not because these drugs lack evidence, but because they are expensive and insurers use policy mechanisms—step therapy, biosimilar mandates, arbitrary severity thresholds—to delay or substitute cheaper alternatives. Denials are common even when your rheumatologist, dermatologist, or gastroenterologist has documented disease severity, prior treatment failures, and a clear clinical rationale. This guide will show you how to overturn those denials using the same clinical guidelines and trial data that insurers' own medical policies cite.

Why Insurers Deny Specialty Biologics

1. Step Therapy / "Fail First" Requirements

The insurer demands you try one or more cheaper drugs before approving the biologic your doctor prescribed. Common patterns:

• Conventional synthetics before biologics: "You must fail methotrexate (MTX), sulfasalazine, or leflunomide for rheumatoid arthritis before any biologic."
• TNF inhibitors before IL-17/IL-23/JAK inhibitors: "You must fail Humira or Enbrel before Skyrizi, Cosentyx, or Rinvoq."
• Biosimilar step therapy: "You must try the biosimilar Hyrimoz or Cyltezo before brand Humira," even if you're already stable on the brand.
• Apremilast (Otezla) before biologics: "You must fail Otezla before Stelara for psoriatic arthritis or psoriasis," despite Otezla being a different class with lower efficacy.

2. Insufficient Severity Documentation

The denial states your disease isn't "severe enough." Insurers often impose thresholds not found in FDA labeling:

• "PASI score must be ≥12" (psoriasis).
• "DAS28-CRP must be >5.1" (rheumatoid arthritis).
• "EASI must be ≥20" (atopic dermatitis).
• "Body surface area (BSA) <10%" (psoriasis), ignoring high-impact sites like hands, feet, face, or genitals.

These numeric cutoffs appear in insurer medical policies but contradict ACR, AAD, and other guidelines that emphasize individualized assessment and functional impairment.

3. Missing Labs or "Not Medically Necessary" Screening

The denial cites lack of tuberculosis screening (QuantiFERON or PPD), hepatitis B/C panels, or recent complete blood count (CBC). Some insurers also require documentation of vaccination status (pneumococcal, influenza, hepatitis B) before approving immunosuppressants.

4. Contraindication to a Preferred Drug

You have a documented contraindication to the insurer's preferred first-line biologic (typically a TNF inhibitor), but the denial doesn't acknowledge it or asks for additional proof. Examples:

• History of demyelinating disease (multiple sclerosis, optic neuritis).
• Moderate-to-severe heart failure (NYHA class III/IV).
• Active or high-risk latent tuberculosis without prophylaxis.
• Active hepatitis B infection.

Insurers sometimes ignore chart notes and demand a formal letter explaining why TNF inhibitors are contraindicated.

5. Biosimilar Substitution on Stable Therapy

The insurer denies continuation of your current brand-name biologic (e.g., Humira) and requires a non-medical switch to a biosimilar (e.g., Cyltezo, Hyrimoz, Amjevita) to save costs. This is increasingly common but controversial; many state laws restrict non-medical switching, and clinical societies warn against forcing stable patients to switch for non-clinical reasons.

---

The Citations Insurers Respect

Insurers write medical policies that reference specific clinical guidelines and head-to-head trials. When you appeal, cite these by name, author, journal, and year—the same way the insurer's own medical director would. Here are the highest-authority sources for biologic appeals:

Clinical Practice Guidelines

• ACR 2021 Rheumatoid Arthritis Guideline (Fraenkel et al., Arthritis Care & Research 2021;73:924): Recommends biologic or targeted synthetic DMARDs (bDMARD/tsDMARD) after inadequate response to methotrexate; states no strong preference among TNF, IL-6, IL-17, IL-12/23 inhibitors, or JAK inhibitors.
• ACR/SAA/SPARTAN 2019 Axial Spondyloarthritis Guideline (Ward et al., Arthritis & Rheumatology 2019;71:1599): Strongly recommends TNF inhibitors or IL-17 inhibitors for active ankylosing spondylitis; no requirement to fail one class before the other.
• ACR/NPF 2018 Psoriatic Arthritis Guideline (Singh et al., Arthritis & Rheumatology 2019;71:5): TNF inhibitors are first-line biologic; IL-17, IL-12/23, and JAK inhibitors are conditionally recommended depending on skin involvement and peripheral vs. axial disease.
• AAD-NPF 2019/2020 Psoriasis Guidelines (Menter et al., Journal of the American Academy of Dermatology 2019;80:1029): Biologics are appropriate for moderate-to-severe psoriasis defined as BSA >10%, PASI >12, or involvement of high-impact areas (face, hands, feet, genitals, nails) regardless of BSA.
• AGA 2020 Crohn's Disease Guideline (Feuerstein et al., Gastroenterology 2021;160:2496): Favors early biologic therapy over step-up care for moderate-to-severe Crohn's; anti-TNF and anti-integrin therapies both first-line.
• AGA 2020 Ulcerative Colitis Guideline (Feuerstein et al., Gastroenterology 2020;158:1450): Biologics (TNF, integrin, IL-12/23 inhibitors) for moderate-to-severe UC.
• GINA 2024 (Global Initiative for Asthma): Step 5 add-on biologics (anti-IgE, anti-IL-5, anti-IL-4Rα) for severe uncontrolled asthma with Type 2 inflammation (eosinophils ≥300/µL or FeNO ≥25 ppb).
• Hidradenitis Suppurativa Foundation / North American Clinical Management Guidelines 2019 (Alikhan et al., JAAD 2019;81:91): Adalimumab (Humira) is the only FDA-approved biologic for HS Hurley stage II/III.
• EULAR 2022 RA Guideline (Smolen et al., Annals of the Rheumatic Diseases 2023;82:3): Reinforces treat-to-target; bDMARD or JAK inhibitor after csDMARD failure.

Head-to-Head Trials (Use When Your Insurer Demands "Preferred" Drug First)

• SELECT-COMPARE (Fleischmann et al., Arthritis & Rheumatology 2019;71:1788): Rinvoq (upadacitinib) superior to Humira (adalimumab) for RA—higher ACR50 response rates.
• IXORA-S (Reich et al., British Journal of Dermatology 2017;177:1014): Taltz (ixekizumab) superior to Stelara (ustekinumab) for moderate-to-severe psoriasis.
• CLEAR (Thaçi et al., JAAD 2015;73:400): Cosentyx (secukinumab) superior to Stelara for psoriasis PASI 90 response.
• VOYAGE 1 & 2 (Blauvelt et al., JAAD 2017;76:405): Tremfya (guselkumab) superior to Humira for psoriasis PASI 90 at week 48.
• VARSITY (Sands et al., NEJM 2019;381:1215): Vedolizumab superior to adalimumab for ulcerative colitis clinical remission and endoscopic improvement.

These trials demonstrate that newer biologics or JAK inhibitors often outperform TNF inhibitors—yet insurers still mandate TNF-first policies based on cost, not outcomes.

---

How to Argue Against Each Denial Reason

Fighting Step Therapy: "You Must Fail MTX / TNFi / Biosimilar First"

If the insurer requires MTX or another conventional DMARD before any biologic:

1. Document adequate trial and failure. An "adequate trial" for methotrexate in RA is typically ≥12 weeks at ≥15–25 mg/week (ACR 2021). Provide:

- Start date, max dose reached, duration.

- Objective measure of non-response: DAS28-CRP, CDAI, or PASI score pre- and post-treatment.

- Reason for discontinuation: lack of efficacy, intolerable side effects (nausea, hepatotoxicity, cytopenias), or contraindication.

2. Cite guideline language. ACR 2021 RA guideline (Fraenkel, p. 929): "We conditionally recommend starting a biologic or tsDMARD rather than triple therapy in patients with moderate-to-high disease activity despite MTX monotherapy." This supports moving directly to a biologic after MTX fails—no requirement to try sulfasalazine, leflunomide, or triple therapy.

3. For Crohn's or UC: AGA 2020 Crohn's guideline (Feuerstein, p. 2499) states: "We suggest the use of anti-TNF agents as first-line therapy over conventional therapy for induction of remission in patients with moderate to severe CD." This refutes "fail 5-ASA and steroids first" policies.

If the insurer requires a TNF inhibitor before an IL-17/IL-23/JAK inhibitor:

1. Check if you've already failed a TNFi. If you've tried Humira, Enbrel, or Remicade and had primary non-response, secondary loss of response, infusion reactions, or injection-site reactions, document it with dates, doses, and lab/clinical scores.

2. Cite "no preference" language. ACR 2021 RA (Fraenkel, p. 936): "Among biologic DMARDs, we conditionally recommend any bDMARD... We did not find sufficient evidence to recommend one agent over another." This contradicts insurer mandates to try TNFi first.

3. Use head-to-head data. If your doctor prescribed Rinvoq for RA and the insurer demands Humira first, cite SELECT-COMPARE: "Rinvoq achieved superior ACR50 response vs. Humira at 12 weeks (45% vs. 30%, p<0.001; Fleischmann 2019)." Argue that requiring a less effective drug first is not evidence-based.

4. For psoriasis: AAD-NPF 2019 (Menter, p. 1044) states biologics are appropriate for moderate-to-severe disease; the guideline does not require TNF inhibitors before IL-23 or IL-17 inhibitors. Cite VOYAGE or CLEAR if your insurer prefers Humira over Tremfya or Cosentyx.

If the insurer forces a biosimilar switch despite stable disease:

1. Know your state law. As of 2026, ~40 states have biosimilar substitution laws requiring pharmacist notification and physician consent. Check if your state prohibits non-medical switching (switching a stable patient for cost reasons without clinical cause).

2. Cite continuation of care. ACR's position statement (2018, updated 2023) supports biosimilar use but opposes mandatory switching of stable patients without shared decision-making. Write: "Patient has been stable on brand Humira for [X months], with DAS28-CRP [score], no adverse events. Non-medical switch introduces risk of nocebo effect, loss of efficacy, and immunogenicity. Continuation is medically necessary."

3. Reference the appeal to medical necessity, not just preference. Insurers will argue "biosimilars are interchangeable." Counter: "While biosimilars are similar, they are not identical. [Patient name] has achieved remission and switching introduces unnecessary clinical risk without medical justification. ACR and EULAR guidelines emphasize maintaining stable therapy."

---

Fighting "Insufficient Severity"

If the denial cites a numeric threshold (PASI <12, DAS28 <5.1, EASI <20):

1. Pull the guideline language that refutes the cutoff.

- AAD-NPF 2019 Psoriasis (Menter, p. 1030): "Moderate to severe psoriasis is defined as BSA >10%, PASI >12, or involvement of 'special areas' such as hands, feet, face, genitals, intertriginous areas, or nails." Even if PASI or BSA is low, high-impact sites justify biologics.

- ACR 2021 RA (Fraenkel): Uses moderate-to-high disease activity based on any validated measure (DAS28-CRP ≥3.2 is moderate; no requirement for >5.1).

2. Provide objective disease-activity scores at time of prescription:

- Rheumatoid arthritis: DAS28-CRP, CDAI, RAPID3.

- Psoriasis: PASI, BSA, Dermatology Life Quality Index (DLQI).

- Atopic dermatitis: EASI, IGA, SCORAD.

- Crohn's: Harvey-Bradshaw Index (HBI) or Crohn's Disease Activity Index (CDAI).

- Ulcerative colitis: Mayo score or partial Mayo.

- Ankylosing spondylitis: BASDAI, ASDAS-CRP.

3. Document functional impairment and quality of life. If numeric score is borderline, add: "Patient unable to work due to hand psoriasis" or "Patient has failed to achieve remission on MTX; current DAS28-CRP 4.8 indicates persistent moderate disease activity (ACR threshold for escalation is ≥3.2)."

4. For "special site" psoriasis: Attach photos (if HIPAA-compliant) or a letter: "Patient has palmoplantar psoriasis affecting 5% BSA but severe functional impairment (unable to grip, walk without pain). AAD-NPF 2019 explicitly includes high-impact sites as indication for biologics regardless of BSA."

---

Fighting "Missing Labs / Not Medically Necessary Screening"

Most insurer policies do require TB and hepatitis screening before biologics. If your denial is purely administrative (labs not submitted), this is an easy fix:

1. Obtain and submit:

- TB test: QuantiFERON-Gold or PPD within past 12 months.

- Hepatitis B: HBsAg, anti-HBc, anti-HBs.

- Hepatitis C: HCV antibody.

- CBC, CMP (to establish baseline).

2. If you have latent TB: Document that you've started or completed isoniazid (INH) prophylaxis. CDC and ACR both recommend treating latent TB before TNFi.

3. Resubmit the prior authorization with lab results. Often the insurer will approve immediately once screening is documented.

If labs are complete but the insurer still denies for "not medically necessary," treat this as a severity or step-therapy denial (see sections above).

---

Fighting Contraindication Denials

If you have a contraindication to TNF inhibitors (e.g., MS, heart failure, active TB) but the insurer still requires TNFi step therapy:

1. Provide a contraindication letter. Your physician should write:

- Diagnosis and date of contraindication (e.g., "Patient diagnosed with relapsing-remitting MS in 2022; MRI 3/2026 shows new lesions. TNF inhibitors are contraindicated due to risk of demyelination exacerbation.").

- Guideline reference: FDA labeling for Humira, Enbrel, Remicade all list demyelinating disease and moderate-to-severe heart failure (NYHA III/IV) as warnings or contraindications.

2. Request exemption from step therapy. Many states have step-therapy override laws allowing exemption if the required drug is contraindicated. Check your state law (e.g., California AB 2222, Texas HB 2536).

3. Cite the alternative drug's evidence base. If contraindicated to TNFi and prescribed Cosentyx (IL-17i) or Stelara (IL-12/23i):

- AxSpA: ACR/SAA/SPARTAN 2019 (Ward, p. 1604) conditionally recommends IL-17i without requiring TNFi failure.

- PsA: ACR/NPF 2018 (Singh) conditionally recommends IL-17i and IL-12/23i for TNFi-naive patients with predominant skin disease.

---

What We Do

We help patients and their physicians draft physician-ready appeal letters that cite the ACR, AAD, AGA, GINA, and EULAR guidelines by name, include the head-to-head trial data insurers' own medical policies reference, and directly refute the step-therapy, severity, and biosimilar-substitution rationales used in denials. Our process is straightforward: you upload your denial letter and clinical records, we identify the insurer's specific policy citations and denial template, and we generate a 1.5–2 page appeal letter ready for your physician to review, sign, and submit. We do not give medical advice—we translate your doctor's clinical judgment into the language of insurance medical policy and peer-reviewed evidence.

---

Sources

1. Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research 2021;73(7):924–939.

2. Ward MM, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis & Rheumatology 2019;71(10):1599–1613.

3. Singh JA, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & Rheumatology 2019;71(1):5–32.

4. Menter A, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80(4):1029–1072.

5. Feuerstein JD, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158(5):1450–1461.

6. Feuerstein JD, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160(7):2496–2508.

7. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. www.ginasthma.org.

8. Alikhan A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol 2019;81(1):91–101.

9. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82(1):3–18.

10. Fleischmann R, et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis & Rheumatology 2019;71(11):1788–1800.

11. Reich K, et al. Ixekizumab compared with ustekinumab in moderate-to-severe plaque psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol 2017;177(4):1014–1023.

12. Thaçi D, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015;73(3):400–409.

13. Blauvelt A, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial. J Am Acad Dermatol 2017;76(3):405–417.

14. Sands BE, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med 2019;381(13):1215–1226.